Article
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies.
Liver international : official journal of the International Association for the Study of the Liver - 1 Apr 2017
Di Maio Velia C, Cento Valeria, Lenci Ilaria, Aragri Marianna, Rossi Piera, Barbaliscia Silvia, Melis Michela, Verucchi Gabriella, Magni Carlo F, Teti Elisabetta, Bertoli Ada, Antonucci FrancescoPaolo, Bellocchi Maria C, Micheli Valeria, Masetti Chiara, Landonio Simona, Francioso Simona, Santopaolo Francesco, Pellicelli Adriano M, Calvaruso Vincenza, Gianserra Laura, Siciliano Massimo, Romagnoli Dante, Cozzolongo Raffaele, Grieco Antonio, Vecchiet Jacopo, Morisco Filomena, Merli Manuela, Brancaccio Giuseppina, Di Biagio Antonio, Loggi Elisabetta, Mastroianni Claudio M, Pace Palitti Valeria, Tarquini Pierluigi, Puoti Massimo, Taliani Gloria, Sarmati Loredana, Picciotto Antonino, Vullo Vincenzo, Caporaso Nicola, Paoloni Maurizio, Pasquazzi Caterina, Rizzardini Giuliano, Parruti Giustino, Craxì Antonio, Babudieri Sergio, Andreoni Massimo, Angelico Mario, Perno Carlo F, Ceccherini-Silberstein Francesca
Abstract excerpt
BACKGROUND & AIMS: Despite the excellent efficacy of direct-acting antivirals (DAA) reported in clinical trials, virological failures can occur, often associated with the development of resistance-associated substitutions (RASs). This study aimed to characterize the presence of clinically relevant RASs to all classes in real-life DAA failures. METHODS: Of the 200 virological failures that were analyzed in 197...
Read the complete abstract on PubMed